PocketEdge
← All news

Desk note · industry · Pharmaceuticals / emerging markets

Torrent Pharma plans to sell semaglutide in Brazil within nine months

Torrent Pharmaceuticals said on 25 October 2026 it expects to launch semaglutide in Brazil over the next six to nine months as it chases growth in a market where its local revenues rose 38% in the September quarter after a large competitor entered the generic GLP-1 segment.

25 Oct 2026 · 2 min read

Key takeaways

  • •Managing director Aman Mehta told reporters on 25 October that Torrent aims to introduce semaglutide in Brazil within six to nine months.
  • •The drug is a GLP-1 therapy used for Type 2 diabetes and, in some formulations, obesity; Torrent has launched it in India and is now pushing overseas.
  • •Mehta linked the Brazil plan to brisk growth in the country, including a 38% revenue jump in the September quarter as generic semaglutide competition accelerated.

What's going on here?

On 25 October 2026, Torrent Pharmaceuticals Ltd management spoke to journalists about the company’s GLP-1 ambitions beyond India. Managing director Aman Mehta said Torrent plans to launch semaglutide in Brazil over the next six to nine months. Semaglutide belongs to the GLP-1 receptor agonist class used to treat Type 2 diabetes and, where regulators allow, obesity. Torrent has so far commercialised the molecule domestically and is now targeting Latin America’s largest healthcare market. Mehta noted that Torrent’s Brazil business grew about 38% year on year in the quarter ended September 2026, helped in part by a major local player’s entry into generic semaglutide, which expanded the category faster than standalone launches would have. The timeline is management guidance, not a regulatory approval order, but it signals how Indian pharma exporters are sequencing obesity-care molecules after domestic rollouts.

What does this mean?

GLP-1 drugs sit at the intersection of chronic disease and lifestyle medicine, so demand can scale quickly when prices fall and doctors gain comfort with prescribing. Brazil’s public and private payers watch budget impact closely, which is why generic entrants can turbocharge volumes even for followers like Torrent. Export launches require local filings, stability data and often partnership with distributors who understand hospital formularies. For India’s API ecosystem, sustained overseas semaglutide demand supports plant utilisation if patent cliffs and supply chains stay orderly. Competitors including Dr Reddy’s Laboratories have discussed their own semaglutide supply restarts, so the race is as much about reliable manufacturing as brand detail.

Why should I care?

If you invest in Indian pharma, treat Brazil timelines as option value on top of domestic obesity narratives, not guaranteed revenue next quarter. Healthcare administrators in emerging markets should model how fast GLP-1 generics compress spend per patient. Patients in India should not assume identical labels or prices abroad, but export success can keep local plants investing in quality. Watch Anvisa filing updates, Torrent’s Brazil revenue disclosures, and peer launches from Dr Reddy’s and Sun Pharma in the same therapy class.

More desk notes

Disclaimer

For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.